Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

–All primary and secondary endpoints were met for both Phase 3 studies (M21-500 and M21-508). – Results support BoNT/E as a novel botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and short duration of effect within 2-3 weeks.

Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines

Atmos Energy

Cardinal Health

Con Ed

Essex Property Trust

Realty Income Corp

Target

Since 1926, dividends have accounted for almost a third of the total return of the S&P 500.

Why Dividend Aristocrats Like AbbVie May Be the Best Contrarian Ideas Now

ATLANTA--(BUSINESS WIRE)---- $ABBV #21_million_Americans_afflicted_with_MDD--Alzamend Neuro Submit IND Application for Phase IIA Clinical Trial for Major Depressive Disorder of Its Next-Generation Lithium Therapeutic Drug AL001.

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AbbVie (ABBV) Q3 Earnings Expected to Decline

Devon Energy

Kellogg

Microsoft

NextEra Energy

Pfizer

Recently, investors searching for dividend stocks to buy have seen more opportunity. Some looking for income over a longer term horizon have flooded into the bond market.

7 Dividend Stocks to Buy and Hold Forever and Ever

Amcor Plc

Colgate-Palmolive

Chevron

Lowe's

PepsiCo

With market uncertainty practically being the only form of certainty available, investors should consider dividend aristocrats. By definition, companies under this category belong in the S&P 500 index which consistently raises their dividends for at least the past 25 years.

7 Dividend Aristocrats to Batten Down the Hatches

AbbVie's valuation is elevated, though it has no major catalysts coming up. It's also seeing sales of its biggest-earning medicine erode rapidly.

Is AbbVie Stock Too Pricey to Touch Right Now?

The US FDA has already approved two directly interchangeable biosimilars to ABBV's Humira, namely Boehringer Ingelheim's Cyltezo and PFE's ABRILADA. The impact on ABBV's sales may be great, since its competitors have priced their biosimilars at notable discounts, with the third interchangeable biosimilar likely to be approved sooner rather than later. Even so, the stock has maintained much of its gains since December 2021, since the Humira patent expiry was well known for years and pessimism was largely priced in.

AbbVie: The Humira Loss May Be Fully Priced In After All

Apple

AGNC Investment

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

BRT Apartments

Blackstone Group

Canadian Imperial Bank of Commerce

My Dividend Stock Portfolio: New September Dividend Record - 98 Holdings With 22 Buys

AbbVie is a leading pharmaceutical company with a strong history and a diverse portfolio of products. The company's flagship product, Humira, has generated significant revenue and it has a pipeline of promising treatments for various diseases. AbbVie's financials show consistent growth and its valuation suggests potential for future value growth.

AbbVie: Q2 Success Sets The Stage For Consistent Growth

Dividend Kings are the most battle-tested dividend payers on Wall Street, with AbbVie being just one of four in the healthcare sector. The pharmaceutical's 4% dividend yield is covered by both earnings and free cash flow and is substantially higher than the 1.6% yield of the S&P 500 index. AbbVie's portfolio of medicines and its pipeline could catalyze a post-Humira rebound.

AbbVie: Why You Should Pay Attention To This High-Yielding Dividend King (Rating Downgrade)

Since its spin-off from Abbott Labs, AbbVie has delivered outstanding performance, surpassing both its parent company and the S&P 500, thanks to the success of Humira. In 2022, AbbVie became the second-largest pharmaceutical company, but despite diversifying into other areas, the impact of Humira's patent cliff in 2023 is affecting its growth. Despite declining Humira sales, AbbVie remains resilient, focusing on new therapies, M&A, and R&D for sustained growth.

AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014

Arbor Realty Trust

Abbott Labs

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

Amazon

American Express

Becton, Dickinson and Co.

Blackrock Inc

Bristol-Myers

Citigroup

Caterpillar

Cisco Systems

CVS Health

Disney

Digital Realty Trust

Duke Energy

Emerson Electric

Enterprise Products Partners

Eaton

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing.

My Dividend Growth Portfolio - Q3 2023 Summary

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs1 Risankizumab met both primary endpoints of non-inferiority for clinical remissiona (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic remissionb at week 48 versus ustekinumab1 Risankizumab showed superiority versus ustekinumab for all ranked secondary endpoints, including achievement of clinical remissiona at week 48, achievement of endoscopic responsec at week 48 and 24, achievement of steroid-free endoscopic remissiond at week 48 and achievement of steroid-free clinical remissione at week 481 Safety results were consistent with the overall safety profile of risankizumab, with no new safety risks identified NORTH CHICAGO, Ill. , Oct. 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (SKYRIZI®, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereafter) compared to ustekinumab (STELARA®, IV dose at week 0 and 90 mg SC every 8 weeks thereafter) in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.1 The data were presented at the United European Gastroenterology (UEG) Week 2023, October 14-17.

AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints

Illinois Tool Works

Kimberly-Clark

S&P Global

Walmart

Of the 500 stocks listed in the benchmark S&P 500 index, only 51 (10%) are considered dividend kings and have increased their dividend payout to stockholders for 50 consecutive years or longer. Dividend kings are often stocks of long-established blue-chip companies that have prioritized returning capital to their shareholders through consistent dividend payments.

7 Dividend Kings to Buy for Royal Returns

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.

AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study

News for AbbVie Stock (ABBV)